• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

trial safety

Biotech

Ultragenyx granted go-ahead to up doses for Angelman therapy

Ultragenyx and partner GeneTx have been given the go-ahead to up the dose in a phase 1/2 Angelman syndrome trial of antisense treatment GTX-102.
Annalee Armstrong Jan 5, 2022 11:11am

Takeda stops narcolepsy clinical trials because of safety signal

Oct 6, 2021 4:45am

Acorda dumps $363M Parkinson’s drug after patient deaths

Nov 20, 2017 8:34am

Theravance COPD drug clears safety study, setting up NDA

Jul 20, 2017 6:44am

Juno ditches lead CAR-T program following patient deaths

Mar 2, 2017 4:03am

EMA updates first-in-human trial guidance

Nov 16, 2016 12:10pm
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
  • ©2022 Questex LLC All rights reserved.
  • Terms of use
  • Privacy Policy